KNKoh Nakata

Koh Nakata

*This is an algorithmically generated author record based on publicly available information.

Koh Nakata has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Two-year cohort study after GM-CSF inhalation therapy for autoimmune pulmonary alveolar proteinosis

    by Koh Nakata, Ryushi Tazawa, Page Research Group, Nobutaka Kitamura, Haruyuki Ishii

    Background: We conducted a phase III investigator-initiated clinical trial (PAGE: NCT02835742) of GM-CSF inhalation therapy for 24 weeks in 64 patients with autoimmune pulmonary alveolar proteinosis (aPAP), and reported its efficacy and safety (Tazawa et al., N Engl JMed, 2019;381:923). Objective: To know the duration of treatment effect, the presence or absence of late-onset side effects, and predictors of poor prognosisafter PAGE trial. Methods: A survey was started immediately after the end of the trial, and the prognosis was prospectively followed for 2 years. EDC was applied for data collection, data management, monitoring and statistical analysis. This study was conducted in compliance with the Declaration of Helsinki. Results: Of the 64 PAGE participants, 61 gave informed consent and were followed up for 2 years. To summarize the results, (1) the oxygenation-improving effect of GM-CSF inhalation therapy was transient, i.e., the improvement in arterial oxygen partial pressure in the GM-CSF group was greater than that in the placebo group until one year later. (2) The period without additional treatment was affected by whether %VC at the time of enrollment was greater or less than 80%. (3) No late side effects were observed. Discussion: A previous report also cited %VC more than 80% as a prognostic threshold (Tazawa et al., Chest, 2014), which was also confirmed in this study. As a guideline for therapeutic intervention, it is important to manage the %VC so that it does not fall below 80%.


  • Open Access

    Fluorometric Quantification of Human Platelet Polyphosphate Using 4′,6-Diamidine-2-phenylindole Dihydrochloride: Applications in the Japanese Population

    by Taisuke Watanabe, Yutaka Kitamura, Hachidai Aizawa, Hideo Masuki, Tetsuhiro Tsujino, Atsushi Sato, Hideo Kawabata, Kazushige Isobe, Koh Nakata, Tomoyuki Kawase

    Polyphosphate (polyP), a biopolymer of inorganic phosphate, is widely distributed in living organisms. In platelets, polyP is released upon activation and plays important roles in coagulation and tissue regeneration. However, the lack of a specific quantification method has delayed the in-depth study of polyP. The fluorescent dye 4′,6-diamidine-2-phenylindole dihydrochloride (DAPI) has recently received attention as a promising probe for the visualization and quantification of cellular polyP levels. In this study, we further optimized quantification conditions and applied this protocol in quantification of platelet polyP levels in a Japanese population. Blood samples were collected from non-smoking, healthy Japanese subjects (23 males, 23 females). Washed platelets were fixed and probed with DAPI for fluorometric determination. PolyP levels per platelet count were significantly higher in women than that in men. A moderate negative correlation between age and polyP levels was found in women. Responsiveness to CaCl2 stimulation was also significantly higher in women than that in men. Overall, our optimized protocol requires neither purification nor degradation steps, reducing both the time and bias for reproducible quantification. Thus, we suggest that despite its low specificity, this DAPI-based protocol would be useful in routine laboratory testing to quantify platelet polyP levels efficiently and economically.